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ABSTRACT 
 
Effect and Time Course of Acute Red Wine Consumption on Blood Antioxidant Capacity 
and Arterial Distensibility in Male Smokers 
(May 2011) 
 
Rohan Elizabeth Krehbiel, B.S., University of Kentucky 
M.S., Appalachian State University  
Chairperson: Lisa McAnulty 
INTRODUCTION: It is well known that smoking cigarettes leads to oxidative stress 
and is harmful to endothelial function.  Research has previously demonstrated that 
antioxidants found in red wine can counteract the negative effects of reactive oxygen species 
caused by oxidative stress.  The current study utilized a crossover design and investigated 
antioxidant capacity and vascular performance after smoking cigarettes and consuming wine. 
METHODS: Participants included eight male smokers between the ages of 21 and 35.  
These individuals attended an orientation session where baseline anthropometric measures 
were obtained one week prior to the beginning of the study.  Participants then reported to the 
lab where they were randomly assigned to the wine or control group and the following week 
crossed over into the opposite group.  The wine group consumed 300mL of muscadine red 
wine immediately following the baseline measures of arterial distensibility and blood 
samples.  Smoking occurred 45 minutes and 2 hours and 45 minutes following wine 
consumption.  Arterial distensibility measures and blood samples were again collected at 
these two time points.  The control group followed the same procedure but did not consume 
 
  v 
wine.  Outcome variables included plasma antioxidant capacity (Ferric Reducing Ability of 
Plasma, FRAP; Oxygen Radical Absorbance Capacity, ORAC) and vascular measures 
(arterial distensibility).  A 2 (treatments) x 3 (times) repeated measures analysis of variance 
was used to evaluate the main effects of treatment, time, and treatment time interaction.  
RESULTS: The results indicate that when given wine, the participants‟ blood antioxidant 
capacity increased in the FRAP assay (p=0.046).  Additionally, the vascular measures 
showed a significant difference at time 3 between the wine and control groups (p=0.030).  
ORAC was not significantly different between groups or time periods. CONCLUSION:  In 
conclusion, the results of the study suggest that drinking red wine while smoking cigarettes 
may increase antioxidant capacity but does not provide health benefits related to vascular 
performance.  
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INTRODUCTION 
 
Oxidative Stress 
In the body, the balance between the formation of reactive oxygen species (ROS) and 
the reactions that turn the ROS into harmless end products is known as oxidative stress (1).  
Free radicals are ROS formed during the metabolism of oxygen or the metabolism of foreign 
compounds (1).  Examples of foreign compounds consist of environmental factors, or 
exogenous agents, and  include cigarette smoke, pollution, and exposure to ionizing and 
ultraviolet radiation (2).  An endogenous factor that creates ROS occurs during the 
metabolism of oxygen, which the body consumes in large amounts during cardiovascular 
exercise.  The formation of ROS is natural and occurs constantly.  Consequences of oxidative 
stress include DNA damage or mutation, cell death by apoptosis or necrosis (3), lipid 
damage, and protein damage (2).  Cardiovascular disease, neurodegenerative disease, cancer, 
and the aging process are also consequences of oxidative stress.  The connection between 
these diseases and oxidative stress is the alteration of DNA, lipids, and protein damage (2).  
As an example, cigarette smoke exposure leads to the formation of ROS, which leads to 
oxidative stress, which leads to DNA damage, which can then lead to cardiovascular disease, 
emphysema, and/or cancer.  
Acute Cigarette Smoking Effects and Vascular Performance 
 Approximately 45.9 million men and women smoke cigarettes across the United 
States (4).  All of these people are at risk for many diseases because they smoke cigarettes, 
which change arterial function, creating multiple risk factors for cardiovascular disease (5).  
Previous research suggests the antioxidants in red wine could help to reduce the risk of these 
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diseases in cigarette smokers by combating the free radicals (6, 7).  The free radicals found in 
cigarette smoke come from many different sources, and it is possible that exposure to these 
free radicals is one of the first steps in developing cancer, hypertension, atherosclerosis, and 
cardiovascular disease in general.   
One of the endogenous free radicals, nitric oxide (NO), is produced in decreased 
amounts with both passive and active cigarette smoke exposure.  NO acts as a communicator 
for cells in many processes in the body, including blood pressure regulation, 
neurotransmission, controlling the immune system, inhibiting platelet aggregation, and more 
(8, 9).  It also acts as a relaxation factor for the endothelium (10).  With a deficiency of NO, 
hypertension is induced (11).  Rocchi et al. (12) found higher concentrations of NO in non-
smokers as compared to smokers.  A specific type of NO, endothelial NO, regulates 
physiological vasodilatation and inhibits platelet aggregation in order to better support blood 
flow and support an anti-atherogenic state in the endothelium (9, 12, 13).  The availability of 
endothelial NO decreases when an excessive amount of ROS are present in the body.  This 
decrease is due to the inactivation of NO caused by ROS by the formation of cytotoxic 
species (11).  The decrease of endothelial NO causes a hyper-expression of vascular cell 
adhesion, an increase in homocysteine, and a reduction in vasodilator response, thereby 
marring vascular homeostasis.  Rocchi et al. (12) reported that homocysteine was found in 
increased concentrations in the smokers, demonstrating an inverse relationship with NO in 
the blood.  This inverse relationship causes damage to the endothelial lining.  Homocysteine 
is an amino acid derivative that is a metabolite of another amino acid, methionine.  When 
homocysteine is not broken down in the body, concentrations rise and increase the risk for 
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atherosclerosis (1).  Tying all of these factors together, decreased NO, increased ROS, and 
increased homocysteine, result in a favorable setting for the development of atherosclerosis.  
Individuals who smoke cigarettes tend to have increased oxidative stress and 
decreased levels of antioxidants, mostly caused by the oxidants in cigarettes and a poorer diet 
than those individuals who do not smoke (14).  Smoking also causes endothelial dysfunction, 
with both long-term and acute exposure, through the increase of oxidative stress and decrease 
of NO (6, 10).  Endothelial dysfunction is best described as the impaired function of 
endothelial cells located in the arteries.  This results in abnormalities in vasomotor control, 
the breakdown of fibrin and blood clots in the artery, and an inflammatory response (1).  
These abnormalities can lead to atherosclerosis and other forms of cardiovascular disease.  
Atherosclerosis occurs when the arteries experience hardening and narrowing.  This does not 
allow enough blood flow through the artery and can eventually lead to blood clots.  The 
hardening of arteries can stem from either acute or chronic inflammation of the artery, caused 
by endothelial dysfunction and other mechanisms (15).  In simpler terms, smoking cigarettes 
leads to oxidative stress which leads to endothelial dysfunction.  This leads to atherosclerosis 
and cardiovascular disease which greatly inhibits an individual‟s vascular performance.  
When the arteries cannot conduct the passage of enough blood to all the parts of the body, the 
body will not perform as well as it should.  
 Arterial distensibility is the ability of an artery to expand, allowing more blood to 
flow through.  When the artery is more elastic, it absorbs energy during the systolic phase of 
the pulse flow.  By absorbing this energy, the artery reduces the cardiac work during a given 
cardiac output.  Pulse wave velocity is the best known measure of arterial distensibility, 
because the two are inversely related (16).  Pulse wave velocity is how fast the pulse moves 
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along the vessel wall (17, 18).  The quicker the pulse moves, the stiffer the artery; the slower 
the pulse moves, the more elastic the artery.  When the artery takes the time to actually 
surround the pulse and help push it through, it flows through more slowly.  If the artery is not 
moving around the pulse, then the pulse slides right through the artery, making the time 
between pulse waves quicker.  The stiffer the artery, the greater the risk factor is for that 
individual to experience cardiovascular disease.  The carotid-femoral pulse wave velocity is 
the measure used most often and is widely accepted as the measurement for aortic stiffness 
(5, 18, 19).  Cigarette smoking has been known to increase the carotid-femoral pulse wave 
velocity measures, potentially causing this stiffness.  Both long and short term cigarette 
smoking exhibit increased pulse wave velocity.  This result is related to nicotine.  Nicotine 
causes catecholamine concentrations to rise which stimulates the sympathetic ganglia, 
impairing NO generation, finally leading to endothelial dysfunction (5, 20). 
Red Wine and Antioxidants 
Antioxidants counteract oxidants and ROS.  Red wine is commonly known to have 
high amounts of antioxidants.  Interestingly, there are some wines that have high 
concentrations of polyphenols but show a lower antioxidant capacity, or vice versa.  The red 
grapes used to make red wine contain polyphenols, and the concentrations of polyphenols 
can vary greatly from wine to wine depending on varying growth conditions for the grapes 
used (21).  The principle polyphenols in red wine include the following: procyanidins, 
anthocyanins, quercetin, and resveratrol (22).  Procyanidins are made up of oligomeric 
catechins that are covalently linked together.  These compounds usually occur with 
monomeric catechins and epicatechins.  Procyanidins affect  the vascular system in a positive 
manner by increasing plasma antioxidant activity, decreasing platelet aggregation, and 
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increasing NO production (22).  These three effects counteract the negative effects brought 
on by atherosclerosis and endothelial dysfunction.  
Cao et al. (23) observed increased antioxidant capacity in elderly women after 
consuming red wine.  The study assessed the antioxidant capacity of red wine, spinach, 
strawberries, and vitamin C.  Three different antioxidant assays were utilized which were 
comprised of the Ferric Reducing Ability of Plasma (FRAP), Oxygen Radical Absorbance 
Capacity (ORAC), and Trolox Equivalent Antioxidant Capacity (TEAC).  The ORAC and 
FRAP assays showed increased antioxidant capacity in urine and serum after consuming red 
wine, strawberries, spinach and vitamin C.  The ORAC and FRAP antioxidant assays are 
explained in detail in the methods section. 
Modun et al. (24) observed an increase in the FRAP concentration by dealcoholized 
red wine.  This means that the increase was due only to the polyphenol content and not the 
alcohol.  However, there is another possible explanation.  When the liver metabolizes 
ethanol, it produces ROS.  So by taking the ethanol out of the wine, the liver does not 
metabolize it and does not produce ROS.  It is possible that there were less ROS to 
neutralize, thereby resulting in the increased FRAP values.  
Another side effect of ROS generation is that it may reduce certain immune cell 
functions.  However, when consuming regular red wine, it was found that the antioxidants 
may scavenge the ROS and defend the immune system against the activities of the ROS (25).  
Therefore, antioxidants might also support immune function.  Antioxidants and polyphenols 
in wine have positive effects on the body in that there is protection from oxidative stress and 
consequent damage in many potentially different systems, specifically, the immune system 
and the cardiovascular system.  
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 The antioxidants and polyphenols that provide health benefits in red wine come from 
the grapes used to make the wine.  Muscadine grapes (Vitis rotundifolia) produce a sweet red 
wine with a significant amount of the phytochemical anthocyanin.  Anthocyanins are an 
antioxidant and can prevent cancer and the tumors associated with cancer (26).  
Anthocyanins are the chemical responsible for the dark purple color of the muscadine grape 
and support a healthy blood pressure (27). 
Red Wine and Vascular Performance 
 Moderate alcohol consumption, including red wine, has been touted as a beneficial 
addition to the diet and can provide protection from coronary heart disease as well as its risk 
factors.  The key word is moderate.  If copious amounts of alcohol, including red wine, are 
consumed, it can have detrimental effects on the body (24, 28-32).  Red wine specifically is 
beneficial because of its antioxidant capacity, namely the polyphenol resveratrol.  
Resveratrol has been found to inhibit the oxidation of low-density lipoproteins, protect cells 
from collecting lipids, protect the cardiovascular system, and act as an anti-inflammatory 
agent.  When protecting the cardiovascular system, resveratrol controls the endothelial cell 
growth, helping to prevent endothelial dysfunction (32).  Polyphenols also provide 
vasorelaxing effects in human, rat, and rabbit arteries (29).  Vasorelaxation is important 
because it decreases vascular pressure, which decreases the pulse wave velocity and 
promotes healthy vascular function.  Even though the antioxidants in the red wine provided 
benefits, the alcohol content can have detrimental effects on vascular function.  Zilkens et al. 
(30) found alcoholic beverages increased the blood pressure, most likely a consequence of 
the alcohol content rather than the antioxidant capacity.   
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Antioxidant Capacity Measures 
 When investigating free radical damage, it is important to have accurate assays 
available to assess the antioxidant capacity.  The FRAP and ORAC assays have been used in 
many research studies to assess the antioxidant capacity of red wine and other substances 
(23, 24, 33-36).  Antioxidant capacity can also be referred to as the reducing ability (FRAP) 
of a solution or the ability of a solution to protect against a radical generator (ORAC; 35).  
There are advantages and disadvantages to both assays.  FRAP is quick and simple to 
perform and results are easily reproduced.  It is also a relatively inexpensive assay to run (33, 
36).  However, Cao and Prior (36) demonstrated that it does not measure the antioxidant 
capacity of reducing glutathione, an antioxidant whose concentration is low in humans. This 
is because the reduction action of ferric (Fe
III
) to ferrous (Fe
II
)does not always match the 
action of an antioxidant against a free radical (36). ORAC advantages include being 
standardized, using biologically relevant free radicals, and the integration of degree and time 
of antioxidant reaction.  Using a standardized assay is important because it can be easily 
repeated and is easy to compare results from different laboratories.  Disadvantages when 
assessing antioxidant capacity with ORAC can be the expensive equipment necessary, 
variability amongst data when different equipment is used, and the sensitivity of the assay 
itself (37).   
Red wine and smoking effects 
 The numerous antioxidants found in red wine provide many protective effects to the 
body.  This includes protecting against the ROS produced in the body when a person smokes 
a cigarette.  Two separate studies found that by consuming red wine at the same time as 
smoking, the deleterious effects to endothelial function from the smoke were reversed by the 
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red wine (6, 7).  While both of these studies investigated acute consumption of smoke and 
red wine on endothelial function, neither examined arterial distensibility.  Papamichael et al. 
(7) had 16 participants for their crossover study lasting three days.  Each participant drank 
250 mL of Grand Reserve red wine or Grand Reserve dealcoholized red wine and smoked 
one cigarette.  Flow mediated dilatation was used to assess endothelial dysfunction, and was 
measured after fasting and repeated at 15, 30, 60, and 90 minutes post-wine consumption and 
post-smoking.  Results of this study included that flow mediated dilatation decreased after 
smoking one cigarette but did not change when the participant also drank wine or 
dealcoholized wine.  Karatzi et al. (6) conducted a very similar study to Papamichael et al. 
(7).  They also utilized a crossover design.  The group was comprised of 20 participants who 
experienced three study days consisting of: smoking one cigarette, smoking one cigarette and 
drinking 250 mL of red wine, and smoking one cigarette and drinking 250 mL of 
dealcoholized red wine.  Flow mediated dilatation was also used in this study, being 
measured at fasting, 30, 60, and 90 minutes after the completion of each consumption.  
Results from this study also concluded that after smoking one cigarette flow mediated 
dilatation decreased but did not change significantly after consuming wine or dealcoholized 
wine along with the cigarette.  Also, Karatzi et al. (6) considered the main limitations in their 
own study to be that it did not measure antioxidant capacity or oxidative stress.  Thus, results 
of these two studies did not fully elucidate the relationship between smoking and acute red 
wine consumption. 
Therefore, we sought to investigate the effects of red wine on measures of both 
arterial distensibility and antioxidant capacity.  Additionally, collecting blood samples at 
several time points post wine ingestion provided information about when the antioxidants are 
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at a peak in the blood.  Antioxidant capacity was measured using FRAP and ORAC, and 
changes to the vasculature were directly measured by examining changes in arterial 
distensibility.  By measuring both antioxidant capacity and arterial distensibility, a better 
understanding of the interaction between smoking and red wine consumption was determined 
in each subject.  The hypothesis of this study is that red wine consumption ameliorates the 
deleterious effects of smoking in an acute manner.  The results of this study are important to 
further our understanding of the effects of red wine and polyphenols on the body‟s vascular 
system. 
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METHODOLOGY 
 
Subjects 
 This study was approved by the Institutional Review Board at Appalachian State 
University.  A copy of the Institutional Review Board documents is located in Appendix B.  
Male smokers between the ages of 21 and 35 were recruited as subjects to participate in the 
study.  Fliers and public service announcements were used to recruit the subjects.  A copy of 
the recruitment flier is located in Appendix A.  For inclusion in the study, subjects were 
required to have a history of smoking at least one cigarette per day.  Subjects were excluded 
on the basis of gender, age, and if chronic medication was used.  No exclusions were made 
on the basis of race or color. 
Research Design 
 One week prior to beginning the study, subjects attended an orientation and screening 
session in University Hall.  Informed consent, body composition, height, weight, and health 
information were also obtained at this session.  A copy of the health questionnaire used is 
located in Appendix C.  Body composition was assessed using Bioelectrical Impedance. A 
scale from Tanita was utilized, model TBF 300a (Arlington Heights, IL).  Subjects were 
asked to refrain from consuming large-dose vitamin/mineral supplements, herbs, and 
medications during the study‟s entirety.  The subjects were instructed to avoid alcohol and 
over the counter medications 24-hours before the study began each week, as well as caffeine 
and nicotine each morning on the day of the study.  Subjects were instructed on and kept a 
three day food record prior to each test.  
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Testing Sessions 
 The subjects were randomized into two groups, wine (n = 6) and control  
(n = 2). Upon arrival at the laboratory, weight and body composition were obtained again.  
The subjects sat quietly for 10 minutes before participating in a pre-wine consumption blood 
test and arterial distensibility test.  Fourteen mL of blood were taken each time blood was 
drawn.  After the initial tests of the morning, subjects drank 300mL of Duplin red wine while 
sitting or did nothing if they were in the control group.  Forty-five minutes after finishing 
their wine, subjects moved to a designated smoking area and were given five minutes to 
smoke one unfiltered, Camel cigarette.  When the subjects returned to the laboratory at 
approximately1 hour following wine consumption, post consumption arterial distensibility 
tests and blood draws were conducted.  The smoking protocol mentioned previously was 
repeated at approximately 2 hours and 45 minutes post consumption.  At 3 hours post 
consumption, the last blood draw and arterial distensibility test of the day were performed.  
Following these final tests, snacks and water were provided for consumption, and the three 
hour time period following alcohol consumption allowed blood alcohol levels to return to 
normal, thereby enabling the subjects to safely leave the laboratory.  To measure the blood 
alcohol levels in the subjects, each subject was tested with a breathalyzer 15 minutes after 
drinking the wine, at 1 hour, and at 3 hours.  A portable breath tester from Lifeloc 
Technologies (Wheat Ridge, Colorado) was used, model FC10.  This 3 hour time period was 
repeated, after a one-week wash out period, when the subjects crossed over into the opposite 
group. 
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Arterial Distensibility 
 Arterial stiffness is measured by pulse wave velocity. Measuring pulse wave velocity 
is known to be noninvasive, safe, and easy to conduct in any setting while also requiring 
average training before beginning (16, 18, 19).  To measure the pulse wave velocity, the 
distance between the two sites being measured is divided by how many seconds it takes for 
the pulse to travel in the artery (16-18).  In this study, the measurements between sites were 
obtained using a tape measure while the subject was in the supine position.  The first 
measurement was from the left carotid to left femoral arteries and the second was from the 
left carotid to the left dorsalis-pedis arteries.  The SphygmoCor CPV instrument (Itasca, IL) 
was utilized.  The SphygmoCor CPV allows the user to measure pulse wave velocity 
between two arterial locations.  An electrocardiogram was also utilized to monitor the 
subjects while pulse wave velocity was being taken.  In addition to the pulse wave velocity 
measures, radial augmentation index was also measured.  A minimum of 12 pulse contours 
were recorded and analyzed by the computer.  
Blood Collection 
 Each subject had blood drawn three times during each session, making a total of six 
draws for the entire study.  Blood samples were taken pre-wine consumption, 1 hour post-
wine consumption, and 3 hours post-wine consumption.  At 14 mL for each draw, the 
subjects provided a total of 42 mL on each day of the study.  This amount is approximately 
400 mL less than what is typically donated at a blood bank, making it a safe amount to 
collect from the subjects on each day. 
Blood Analysis 
 FRAP and ORAC were used to analyze all blood samples provided by each subject.   
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FRAP 
Reducing refers to when a reactive species, or oxidant, is reduced by the reductant, or 
antioxidant.  In FRAP, a Fe
III
 compound is reduced to the Fe
II
 form (33).  This reduction will 
take place when a reductant, or antioxidant, is present in the substance.  In the in vitro, or test 
tube reaction medium, this reduction results in a blue chromogen.  Therefore, the intensity of 
the blue color correlates to the amount of water soluble antioxidants present in the sample 
(33).  For this study, a working FRAP reagent was composed of acetate buffer, TPTZ (2,4,6 
– tripyridyl-s-triazine) solution, and an iron chloride plus water solution.  Standards and 
samples were analyzed by adding the FRAP reagent and measuring absorbance.  The 
standard was an ascorbate solution made of ascorbic acid and distilled water, and the samples 
were the plasma collected from each participant.  Each sample and standard was measured 
twice to ensure the quality of readings (33).  Directions to complete the FRAP assay are 
located in Appendix E. 
ORAC 
  The ORAC assay was also used in this study to analyze the antioxidant capacity in 
all blood samples.  ORAC is an inhibition method (34).  When a free radical is generated 
during the assay, the inhibition of its action is measured.  The amount of inhibition that 
occurs shows the antioxidant capacity in the sample.  AAPH [2,2′-Azobis(2-amidinopropane) 
dihydrochloride] is used to make the free radicals, and fluorescein  is used as the protein to 
which the free radicals will cause damage.  ORAC measures the ability of an antioxidant to 
extinguish the free radicals in the sample (36).  The standard curve was made using a vitamin 
E analogue, trolox.  The results of the plate samples were measured as trolox equivalents 
(35).  A plate reader, Spectra Max Gemini XPS (Molecular Devices, Inc., Sunnyvale, CA), 
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was used to read the results of ORAC.  In the ORAC plate, there was one well containing 
only fluorescein.  This well acted as an adjuster for the plate reader.  The remaining wells 
contained phosphate buffer, samples, and trolox standards, arranged in a specific order to 
obtain the correct results from the plate reader.  After fluorescein was added to the plate, it 
was incubated which allows the free radicals to cause damage.  When antioxidants were 
present in the sample, the damage to the fluorescence was reduced or inhibited, and allow for 
the measurement of the antioxidant capacity (35).  Directions to complete the ORAC assay 
are located in Appendix F. 
Statistical Analysis 
 A 2 (treatment) x 3 (time) repeated measures analysis of variance was used to 
evaluate the main effects of treatment, time, and treatment time interaction changes.  A 
Bonferroni post-hoc analysis was performed to examine point to point differences.  All 
statistical analyses were performed using SPSS version 17 (IBM, Armonk, NY).  
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RESULTS 
 
Subjects  
Eight male subjects with an average age of 23.88 years completed the study in its 
entirety.  Subject characteristics are presented in Table 1.  Appendix D contains the 
participant descriptive raw data.  
Table 1. Participant Descriptive Information 
 Baseline  Treatment  Control  p Value 
Age (yr) 23.88 ± 4.45 - - - 
Height (in) 69.13 ± 2.64 - - - 
Weight (lbs) 175.25 ± 52.47 173.38 ± 51.42 173.50 ± 51.89 0.870 
BMI (kg/m
2
) 25.64 ± 6.55 25.37 ± 6.42 25.38 ± 6.49 0.906 
Smoking 
(days/month) 
22.75 ± 10.24 - - - 
 
Values are means ± standard deviation; yr = year,
 
in = inches, lbs = pounds,
 
kg/m
2
 = 
bodyweight in kilograms/ height in meters squared.  
 
FRAP 
The results are presented in Figure 1 and the raw data is in Appendix G.  There were 
significant effects of acute red wine consumption on increasing the overall plasma 
antioxidant reducing potential based on the FRAP assay versus Controls (p = 0.046).  There 
were no significant effects on FRAP related to the time course of acute red wine 
consumption, although there was a 17% difference between the wine and control groups at 
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time 2 and an 8% difference at time 3.  In Figure 1, the FRAP values for both the wine group 
and control group started at the same points but by time point 2 they had separated.  The 
wine group FRAP values increased at time point 2, representing an increase in the subjects‟ 
antioxidant capacity.  However, by time point 3 the effect seemed to have worn off based on 
the fact that the FRAP values decreased.  The control group‟s FRAP values actually 
decreased slightly at each time point. 
Figure 1. Ferric Reducing Ability of Plasma (FRAP)   
 
Values are mean ± standard deviation; * Notes significant difference between groups; (n = 
8); hr = hour, min = minutes. 
ORAC 
 The ORAC assay did not indicate any significant differences between treatments 
(Figure 2).  Raw data for the ORAC assay is located in Appendix H.  Three possibilities 
exist, one being that smoking alone was not enough to create a sufficient level of oxidative 
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stress to alter the ORAC assay, or that the wine does not provide enough change in 
antioxidant capacity, or both. 
Figure 2. Oxygen Radical Absorbance Capacity (ORAC) 
 
Values are mean ± Standard Deviation; (n = 8); hr = hour, min = minutes 
Augmentation Index  
 Appendix I contains the raw data for the augmentation index results.  The vascular 
tests completed during the study showed that wine consumption while smoking has a 
negative effect on arterial distensibility.  Figure 3 demonstrates this observation with the 
wine group‟s augmentation index at time 3 increasing significantly (p = 0.030).  A higher 
augmentation index signifies stiffer arteries.  Wine negates the smoking effect on the aorta 
but not immediately.  The wine group increased above the control group showing that wine 
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consumption combined with smoking is worse for arteries than smoking alone.  Therefore, 
the research suggests that drinking red wine while smoking has no protective effects on the 
vascular system and may cause greater harm than smoking alone.  
Figure 3. Augmentation Index (AIX) 
 
Values are mean ± Standard Deviation; * notes sig difference between groups; (n = 8); hr = 
hour, min = minutes.  
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DISCUSSION 
 
 With significant results in FRAP and the arterial distensibility, the present study has 
agreed with previous studies that red wine increases antioxidant concentrations in the plasma 
(6, 7, 23, 28).  In the FRAP results, the decrease of antioxidant capacity in the control group 
was unexpected.  This decrease could be from the subjects‟ exposure to cigarette smoke at 
time points 2 and 3.  Since the subjects did not have the antioxidants in their blood from the 
wine, the ROS from the cigarette smoke could have depleted some of the antioxidants which 
contribute to FRAP.  With decreased concentrations of antioxidants in the body, FRAP 
values became lower.  Our results indicate that drinking red wine while smoking appears to 
have no protective effects on the vascular system and may actually cause greater harm than 
smoking alone.  The alcohol in the wine is potentially the cause of the harm to the vascular 
system.   
According to Zilkens et al. (30), the alcohol in alcoholic beverages, including red 
wine, causes a rise in blood pressure.  The study looked at healthy normotensive men who 
drank beer, red wine, dealcoholized red wine, and partook in abstinence as the control.  
When comparing the blood pressures of their subjects from the dealcoholized red wine and 
control time periods, no significant difference was experienced.  This result led the 
researchers to conclude that the antioxidants in the red wine may not provide protection from 
the blood pressure elevating effects of alcohol.  Another study conducted by Papamichael et 
al. (7) found opposite results from the current study; consumption of red wine, regular or 
dealcoholized, concurrent with smoking ended up decreasing the harmful effects of the 
cigarette smoke on the vascular system.  It has been found that moderate alcohol 
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consumption in conjunction with healthy lifestyle behaviors reduces the risk of a myocardial 
infarction (31).  This study looked at only lifestyle behaviors, using no measurements such as 
pulse wave velocity.  The results of the current study show the exact opposite effect of 
alcohol on the vasculature; it causes harm to the endothelial lining, increasing the risk of 
cardiovascular disease and potentially a myocardial infarction.  
 Physiologically, smoking has an effect on the vasculature.  This could explain why 
the control group has a higher endpoint in the augmentation index than the wine group.  
Augmentation index represents the stiffness of the artery.  It occurs when the incident pulse 
wave and reflected pulse wave meet, and the ratio of the two is expressed as a percentage 
(18, 38).  Stiffness of arteries can be a risk factor attached to cardiovascular disease, making 
this measurement helpful in prognosis (18).  
Limitations 
 Part of the present study‟s focus was the time course of the effects of wine 
consumption.  Unfortunately, there were circumstances beyond the researchers‟ control that 
might have delayed the time course by a few minutes.  These included: not being able to 
draw blood right away, not finding a pulse with the arterial distensibility machine, and 
subjects taking longer than the five minutes allotted to smoke a cigarette.  
 The limited number of subjects participating in the study presented several 
limitations.  The power of interaction was not high enough to detect a small effect of FRAP 
between the two groups.  If there had been more participants, the power of interaction could 
have been higher as well as potentially providing more significant results.  
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It is possible that ORAC did not show any effects because the study protocol did not 
provide enough oxidative stress through smoking to impact the ORAC assay.  ORAC reflects 
the composite and cumulative antioxidant capacity of the blood (34).  
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CONCLUSION 
 
There were significant protective effects of acute red wine consumption compared to 
the control on the overall plasma antioxidant reducing potential, based on the FRAP assay.  
Although FRAP values increased, no significant effects were found related to the time course 
of acute red wine consumption.  Significant protective effects on arterial distensibility were 
found in acute red wine consumption compared to the smoking only treatment.  Over time, 
the protective effects of acute red wine consumption diminished and had no effect on arterial 
distensibility.  This study has shown that drinking red wine while smoking has no protective 
effects on the vascular system and may cause greater harm than smoking alone.  Future 
studies will need to be performed including more subjects with more indices included, such 
as the renin angiotensin aldosterone system.  Blocking the renin angiotensin aldosterone 
system can be a pulse wave velocity modifier, which might change the results presented 
above (19).  Also to be considered would be including a group to consume dealcoholized red 
wine to compare results to measure the affect of the alcohol on the arterial distensibility and 
antioxidant capacity.  
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APPENDIX A 
Recruitment Flier of the Wine Study 
Male Smokers Needed for Red Wine 
Antioxidant Study
• This is a study to investigate the effect of acute red wine 
consumption on blood antioxidant and blood vessel 
performance
Your obligations:
• Attend an orientation and 2 morning test sessions
• Allow professional phlebotomist to collect a total of 6 
blood samples
• Allow technician to perform a safe, painless and non-
invasive blood vessel performance test
You will be provided with:
• $30.00 (upon completion of study)
• Results of all lab tests including assessment of body 
composition
Need an extra $30?
We are looking for male 
smokers ages 21-35 who 
would be willing to drink red 
wine, smoke and give blood 
samples.
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APPENDIX B 
Institutional Review Board Documents 
 APPALACHIAN STATE UNIVERSITY  
  
Informed Consent for Participants in   
Research Projects Involving Human Subjects  
  
Title of Project:  Effect and time course of acute red wine consumption on blood 
antioxidant and vascular performance in male smokers 
 
      Primary Investigator: Lisa McAnulty, Ph.D., R.D.  
 Co-investigators:    Scott Collier, Ph.D.   
      Steven R. McAnulty, Ph.D. 
      Gregory Anoufriev, M.D. 
      Tim Radak, Dr.PH., R.D. 
 
Purpose of this Research/Project   
 
  The purpose of this study is to examine the blood antioxidant and vascular  
performance (blood vessel) effects as well as the time course (1 hour and 3 hours after  
 consumption) of consumption of 300 ml (~10 oz) of red wine from North Carolina in 15  
subjects.  This study will be the first study to incorporate an investigation of the  
ability of red wine consumption to stop or reduce the damaging effects of cigarette  
smoking as measured by state of the art blood vessel performance measures and changes  
in blood antioxidants over time.  Given the large amount of damaging blood vessel  
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effects and blood pressure changes associated with cigarette smoking, this project is  
highly relevant and will have implications for a sizable section of the population.  
 Additionally, given the positive outcomes anticipated, this project could lend support to  
the North Carolina wine industry as well as support possible development of natural  
compounds which might protect the blood vessels from damage.    
 
BRIEF REVIEW  
 
Smoking  
 
  Smoking causes damage to the blood vessels by injuring cells and  
increasing blood pressure, but the exact mechanism still needs to be found. The  
relationships between smoking and cardiovascular disease most likely result from  
multiple mechanisms that interact to contribute to blockage and vessel cell  
damage. Because of the complexity of the interactions between nicotine and  
other components of smoke with the blood vessel cells, the complete mechanisms by  
which smoking contributes to cardiovascular disease are  still not clear.  Interestingly,  
previous research found that healthy subjects that smoked one cigarette and drank 250 ml  
(1 cup) of red wine maintained good blood pressure versus smoking one cigarette without  
wine.  However, blood antioxidants were not examined.  It is possible that the damage caused 
by smoking could be attributed to increased oxygen damage and that 
antioxidants found in red wine could stop or reduce the bad effects on the blood vessel  
cells.  
Blood Antioxidant Capacity and Red Wine Polyphenolic Compounds 
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Certain compounds in red wine can act as antioxidants.  This has led to the belief that 
red wine consumption provides beneficial effects compared to other alcoholic beverages. 
However, studies assessing the effects of red wine consumption on plasma antioxidants and 
oxygen damage in humans have not given final results.   
 There is evidence that at least part of the process responsible for several of the major 
diseases known to contribute to mortality in the United States (for example, heart disease, 
cancer, diabetes, and Alzheimers) is related to oxygen damage and inflammation.  Oxygen 
damage is derived from the formation of compounds known as reactive oxygen species 
(ROS).  Research has shown supplementation with naturally occurring wine  compounds to 
be safer than traditional antioxidants (such as vitamins E and C) and have  many positive 
effects.  The action of these wine chemicals involves antioxidant activities and the killing of 
cancer cells. Functional foods and natural compounds  have great promise to improve health 
and prevent aging-related chronic diseases.  Many of the natural antioxidant compounds 
found in red wine have been found to possess anti-inflammatory, anticancer, and antioxidant 
activities.     
 
II. Procedures  
 
Orientation and Baseline Testing 
 
  The purpose of this study is to examine the blood antioxidant and blood vessel   
performance effects as well as the time course (1 hour and 3 hours post consumption) of 
acute consumption of 300 ml (~10 oz) of red wine from North Carolina within 10 minutes.  
One to two weeks prior to beginning the study, subjects will report to 168B University Hall 
at 4:00 p.m.for orientation, screening, obtaining informed consent, body composition, height 
and weight.  Body composition (% body fat) will be determined using Bioelectrical 
Impedance (BIA).  Subjects will be instructed not to consume alcohol or other over the 
counter medications or supplements 24 hours prior to reporting and to avoid caffeine and 
nicotine use the morning of reporting to the lab until study conclusion.  Each subject will 
keep a 3-day food record prior to the test and be encouraged to maintain normal dietary 
patterns prior to the study.  During orientation, a dietitian will instruct the subjects on how to 
adhere to the dietary restrictions and how to record intake in a food record.   
 
First Laboratory Test 
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After the orientation visit, subjects will report back to the lab in a fasted state at 8:00 
am for the first experimental trial into which the subject was randomized.  Subjects will be 
instructed not to consume alcohol or other over the counter medications or supplements 24 
hours prior to reporting and to avoid caffeine and nicotine use the morning of reporting to the 
lab.  Subjects will have weight and BIA obtained and then sit quietly for 10 minutes before 
having a pre-wine consumption blood vessel performance test and blood draw (1 tablespoon 
or 14 ml blood total).  Subjects will then consume 10 oz (300 ml) of Duplin red wine within 
10 minutes while sitting in the laboratory.  Exactly 45 min later, subjects will move to a 
smoking area outside the building and smoke one cigarette within a five minute period.  
Subjects will then have a post blood vessel  performance test repeated and post-consumption 
blood draw (1 tablespoon or 14 ml blood total).  To examine the time course of blood vessel 
and blood effects, subjects will remain in the lab and 2-h and 45 min later repeat the 
previously described smoking protocol before having a final blood vessel test and blood draw 
approximately 3-h post wine consumption or control.  Before subjects depart the lab after 
each visit, snacks and fluids will be available for subjects to consume after the 3-h testing.  
Also, before being allowed to leave the study site, a breathalyzer test will be performed on all 
subjects to confirm that blood alcohol concentrations are 0.0%. 
 
Washout Period and Second Laboratory Test 
 
All subjects will then not do anything in the lab for a period of 1-wk (washout) and 
then crossover (go into) into the opposing treatment and repeat the above described sequence 
of events as described in the first laboratory test.  The second test will be with or without 
wine depending upon the initial or first laboratory test in which the subject participated.  
Before subjects depart the lab after each visit, snacks and fluids will be available for subjects 
to consume after the 3-h testing.   
 
Blood Sampling 
 
Blood samples will be drawn six times total during the entire experiment which 
includes Pre-consumption, 1-h Post wine consumption, and 3-h Post wine consumption and 
Pre-control, 1-h Post control, and 3-h Post control.  The following tubes of blood will be 
drawn during each sampling time: one x 7 ml (1 tsp)  tube to examine plasma antioxidant 
capacity  and one x 7 ml (1 tsp) tube for another aspect of antioxidant capacity.  This is a 
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total of 84 ml (about 6 tablespoons) of blood for the entire experiment.    The risks related to 
blood sampling will be minimized by having trained technicians perform the procedures.  
Nonetheless, there is a small risk of infection or bruising.  The procedures are identical to 
those successfully used many times in our laboratory.  The local rescue squad is 1 mile from 
our lab, with a documented response time of 2-3 minutes. All subjects will be provided 
instructions for care as well as contact phone numbers for the investigators involved in the 
study.  Universal precautions will be used throughout all blood collections.  This refers to a 
“mindset” or “attitude” taken by the researchers that assumes all blood or body tissues are 
potentially infectious.  In the case of exposure of an experimenter by your blood or tissue, 
that blood will be analyzed for HIV and hepatitis (a positive HIV or hepatitis test will be 
reported to the subject).   
 
Vascular Performance Testing 
 
 Changes in blood flow and blood vessel function will also be measured pre acute 
wine consumption, 1-h post acute consumption, and 3-h post acute consumption using the 
Sphygmacor Cardiovascular Management System Arterial Pulse Wave Velocity and Aortic 
Blood Pressure Waveforms (PWV, ABPW respectively).  All data will be stored and 
analyzed off-line after completion of testing.  Changes in blood flow and blood vessel 
function measured using the Sphygmacor Cardiovascular Management System Arterial Pulse 
Wave Velocity and Aortic Blood Pressure Waveforms assessment of blood flow is 
completely safe, painless, and non-invasive.  A small pen-like probe is placed over your 
carotid artery (side of your neck), over the femoral artery (top of your leg) and ankle artery.  
A transducer (like a microphone) uses ultrasound waves (sound waves which bounce off the 
blood in the blood vessel) to measure the speed and direction of blood flow through an 
artery.  No physical discomfort should be experienced during this test.  Your privacy will be 
upheld with great care during the assessment of the femoral artery, as this is best located near 
the pubic area.  There are no known risks associated with the Doppler ultrasound used in this 
technique. 
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Study Timeline: 
 
 
 
III. Risks  
  
The risks related to blood sampling will be minimized by having trained technicians 
perform the procedures.  Nonetheless, there is a small risk of infection or bruising.  The 
procedures are identical to those successfully used in a previous study.    The local rescue 
squad is 1 mile from our lab, with a documented response time of 2-3 minutes. All subjects 
will be provided instructions for care as well as contact phone numbers for the local hospital 
and the principal investigator.  Universal precautions will be used throughout all blood 
collections.  This refers to a “mindset” or “attitude” taken by the researchers that assumes all 
blood or body tissues are potentially infectious.  In the case of exposure of an experimenter 
by your blood or tissue, that blood will be analyzed for HIV and hepatitis (a positive HIV or 
hepatitis test will be reported to the subject).   
 The measurement of your body composition via BIA will expose you to a small dose 
of electricity.  The amount of alcohol consumed in this study is considered modest and has 
been safely used in a prior research project (unpublished results).  However unlikely, we will 
ask subjects to report any adverse symptoms associated with the amount of wine used in this 
study such as unusual nausea, headache, vomiting, weakness, or mental confusion. Subjects 
will be given the contact information for the lead investigator in case of questions or 
problems.  Excessive alcohol consumption associated with alcoholism is well understood to 
be detrimental both psychologically and physically.  Individuals identified to have alcohol 
problems will not be included in this study (identified through CAGE Questionnaire).  
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Furthermore, before being allowed to leave the study site, a breathalyzer test will be 
performed on all subjects to confirm that blood alcohol concentrations are 0.0%. 
 
IV. Benefits   
  
 The subject will receive results of all tests and $30.00 compensation upon full 
completion of the study.  The NC Quit Line (1-800-Quit-Now or 1-800-784-8669) is 
available to individuals that would like to quit smoking. I understand that no promise or 
guarantee of benefits have been made to encourage participation.  Larger societal benefits 
include potential progress toward methods to minimize detrimental effects from oxidative 
stress associated with certain disease processes.    
 
V. Extent of Anonymity and Confidentiality  
  
 The identity of subjects will not be disclosed in any published documents or shared 
with anyone but the experimenters. 
 
VI. Compensation  
  
Thirty dollars compensation will be given upon full completion of the study. If as a 
result of a research project, the investigator determines that the subject should seek 
counseling or medical treatment, a list of local services will be provided. In the event of 
physical injury resulting from the research procedures, immediate first-aid is provided free of 
charge. No funds have been set aside for medical treatment of any injury or illness resulting 
from this project and the subject assumes full responsibility for any costs. 
 
 
  36 
VII. Freedom to Withdraw  
  
  The subject is free to withdraw from this study at any time without penalty.   
 
VIII. Approval of Research   
  
This research project has been approved, as required, by the Institutional Review 
Board of Appalachian State University.  
 
 _____________________________    _____________________________ 
 IRB Approval Date                               Approval Expiration Date 
 
IX. Subject's Responsibilities  
  
I voluntarily agree to participate in this study. I have the following responsibilities: 
 
1).  The subject will attend an orientation session at 168B University Hall prior to the start of 
the study and agrees to be randomized into Wine or Control groups initially, complete the 
respective protocol, washout for 1-wk, and then crossover into opposing treatment and 
complete the protocol. 
 
2).  The subject agrees to drink 10 oz red wine (wine group) and sit as a control (without 
wine) and smoke one cigarette a total of four times during the entire study.  Subjects agree to 
remain in the lab for 3-h afterwards for testing and safety reasons and undergo testing of 
blood alcohol concentration via portable breathalyzer.  While a subject in this project, 
subjects agree to avoid the use of alcohol and over the counter medications and supplements 
not recommended by a physician 24-h prior to testing and caffeine and nicotine the morning 
of the test.  Should any medications be prescribed by a physician during the course of the 
study, subject will notify an investigator immediately.  Subject agrees and understands that 
depending upon the drug, it may be necessary for the subject to be released from the study 
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without compensation.  Body composition (% body fat) will be determined using BIA at 
Baseline and Pre-acute session.  Blood vessel measurements will be obtained at each blood 
draw.   
 
3.  On the day of acute testing and prior to the test, subjects will not eat anything past 
midnight the previous day before coming to the lab and avoid all caffeine and cigarettes the 
morning of the test.   
 
4.  Blood samples will be collected at Pre, 1-h post, and 3-h post on two separate occasions.  
 
X. Subject's Permission (May be modified in the case of minors or members of 
other vulnerable populations.)  
  
I have read and understand the Informed Consent and conditions of this project. I have had 
all my questions answered. I hereby acknowledge the above and give my voluntary consent:   
                                       
_________________________________________________Date__________  
Subject signature  
  ________________________________________________ Date __________  
 Witness (Optional except for certain classes of subjects)  
  
 Should I have any questions about this research or its conduct, I may contact:  
 Lisa McAnulty   office phone 828-262-2630  
mcanultyl@appstate.edu   
Primary Investigator     
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Julie Taubman                           828-262-7981              
taubmanjl@appstate.edu 
Administrator, IRB                            Telephone                                  e-mail  
Graduate Studies and Research  
Appalachian State University  
Boone, NC  26608  
 
Subjects must be given a complete copy (or duplicate original) of the signed Informed 
Consent.
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Institutional Review Board  
Approval Date:  ___4/27/2010__________  
Expires On:  _4/26/2011____  
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APPENDIX C 
Health Questionnaire 
Subject ID: _______________________  Interviewer‟s Name:__________________ 
Subject‟s Name:____________________  Date (mm/dd/yy):____________________ 
 
HEALTH AND MEDICAL HISTORY QUESTIONNAIRE 
BACKGROUND 
1. What is your highest level of education? 
  __Elementary  __Jr High School __High School  __College
 __Post College 
2. What is your ethnic background? 
 __Hispanic or Latino (Cuban, Mexican, Puerto Rican, South or Central American, or other 
Spanish origin) 
__Not Hispanic or Latino 
3. What is your race? __White (Europe, the Middle East, or North Africa) __ African 
American __ Asian   __ Native Hawaiian/Pacific Islander __ 
American Indian/Alaska Native 
OVERALL HEALTH 
4. How would you rate your present health condition? 
  __Poor  __Fair  __Good __Excellent 
5. Typically, how many days/year are you sick enough to stay in bed?___________ 
 
WEIGHT HISTORY 
6. Has your weight changed more than 10 lbs in the last 12 months? __Yes __No 
 If yes, why: 
 __change in diet __change in physical activity __illness __depression/stress
 __other 
7. Do you have a history of an eating disorder, such as anorexia or bulimia? __No __Yes 
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8. Have you ever smoked? 
 __Never __Not now, but more than 12 months ago __Not now, but within the past 12 
months 
 __Yes, currently smoking 
MEDICAL HISTORY 
9. Please check which of the following conditions you have had or now have.  Also check medical 
conditions in your  family (father, mother, brother(s), or sister(s)). Check as many as apply 
 Personal Family  Medical History 
  □ □  Coronary heart disease, heart attack 
  □ □  Surgery 
  □ □  Angina 
  □ □  High blood pressure 
  □ □  Peripheral vascular disease 
  □ □  Phlebitis or emboli 
HEALTH AND MEDICAL HISTORY QUESTIONNAIRE 
 Personal Family  Medical History 
 
  □ □  Other heart problems (specify:_________________) 
  □ □  Lung cancer 
  □ □  Breast cancer 
  □ □  Prostate cancer 
  □ □  Colorectal cancer 
  □ □  Skin cancer 
 
  42 
  □ □  Other cancer (specify:________________) 
  □ □  Stroke 
  □ □  Chronic obstructive pulmonary disease (emphysema) 
  □ □  Pneumonia 
  □ □  Asthma 
  □ □  Bronchitis 
  □ □  Diabetes mellitus 
  □ □  Thyroid problems 
  □ □  Kidney disease 
  □ □  Liver disease (cirrhosis of the liver) 
  □ □  Hepatitis (A,B,C,D, or E) 
  □ □  Gallstones/gallbladder disease 
  □ □  Osteoporosis 
  □ □  Arthritis 
  □ □  Gout 
  □ □  Anemia (low iron) 
  □ □  Stomach/duodenal ulcer 
  □ □  Rectal growth or bleeding 
  □ □  Cataracts 
  □ □  Glaucoma 
  □ □  Depression 
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  □ □  Substance abuse problems (alcohol, drugs etc) 
  
HEALTH AND MEDICAL HISTORY QUESTIONNAIRE 
 
 
10. Please indicate the approximate number of alcoholic beverages per week. (Beer: one drink = 
one 12-ounce beer; 
       Liquor: One drink = 1.5 ounces of liquor; Wine: One drink = 5 ounces) 
  □ 0 Drinks 
  □ 1-2 Drinks 
  □ 3 or more Drinks 
 
11. Please check any of the following medications (prescription and/or over the counter) you 
currently take regularly. Also give the name of the medication. 
   Medication   Name of Medication 
  □ Heart Medicine  __________________ 
  □ Blood Pressure Medicine __________________ 
  □ Blood cholesterol Medicine __________________ 
  □ Hormones   __________________ 
  □ Birth Control pills  __________________ 
  □ Medicine for breathing/lungs __________________ 
  □ Insulin    __________________ 
  □ Other medicine for diabetes __________________ 
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  □ Arthritis Medicine  __________________ 
  □ Medicine for depression __________________ 
  □ Medicine for anxiety  __________________ 
  □ Thyroid Medicine  __________________ 
  □ Medicine for Ulcers  __________________ 
  □ Pain killer Medicine  __________________ 
  □ Allergy Medicine  __________________ 
  □ HIV/AIDS Medicine  __________________ 
  □ Hepatitis Medicine  __________________ 
  □ Other (please specifiy)  __________________ 
 
HEALTH AND MEDICAL HISTORY QUESTIONNAIRE 
 
Supplement Use 
12. Are you presently using or have you used within the last 12 months the following supplements at 
least three  
      times/week: 
Type of Dietary Supplement 
 
Note:  If calcium and vitamin D are 
taken as one supplement, separate 
into two categories under "single 
vitamin" and "single mineral". 
If a supplement contains more than 3 
components, enter as either 
"multivitamin", "multimineral", or 
"multivitamin/mineral". 
Provide Brand Name 
or Type (i.e., vitamin 
E, calcium, iron, etc.) 
Add important 
comments 
Use Dosage/Ta
b (single 
substances
) & Units 
Cups for 
herbal teas 
Spoons or 
scoops for 
some 
No. 
Tabs 
per time 
point 
No. 
Times: 
Per day 
or 
Per 
week 
Last Used 
(mm/yyyy) 
Multivitamin     NA 
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Multimineral     NA 
      
Multivitamin/mineral     NA 
      
Single vitamin(s)      
      
      
      
      
Single mineral(s)      
      
      
      
      
Herbal dietary supplement(s)      
      
      
      
Herbal tea*  NA    
      
      
Other over-the-counter 
supplement(s) 
     
      
      
      
Fiber Supplement (i.e., 
Metamucil, Fibercon) 
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HEALTH AND MEDICAL HISTORY QUESTIONNAIRE 
 
Physical Fitness, Physical Activity/Exercise 
13.   In general, compared to other persons your age, rate how physically fit you are: 
 1 □  2 □  3 □  4 □  5 □  6 □  7 □  8 □  9 □  10 □ 
 Not at all      Somewhat               Extremely 
 Physically active     physically active              physically fit  
 
14. Outside of your normal work or daily responsibilities, how often do you engage in exercise that at 
least moderately  
increases your breathing and heart rate, and makes you sweat, for at least 20 minutes (such as 
brisk walking, cycling, swimming, jogging, aerobic dance, stair climbing, rowing, basketball, 
racquetball, vigorous yard work, etc.) 
 □ 5 or more times per week □ 3 to 4 times per week □ 1 to 2 times per week 
 □ Less than 1 time per week  □ Seldom or never 
 
15. How much hard physical work is required on your job? 
 □ A great deal □ A moderate amount   □ None 
 
16. How long have you exercised or played sports regularly? 
 
 □ I do not exercise regularly □ less than 1 year □ 1 to 2 years 
 □ 2-5 years  □ 5-10 years    □ more than 10 years 
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Name of personal physician:___________________________________   
Phone #:_______________________ 
Address:______________________________________________________________________
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APPENDIX D 
Demographic Data 
Age 22 23 21 21 21 21 31 31 
Height 71” 71” 73” 65” 70” 67” 69” 67” 
Weight 144 226 134 148 284 149 165 150 
Smoking 
length 
4 years 7 years 6 years 8 years 4 years 3 years 15 
years 
15 
years 
Smoking 
days/month 
30 7 10 30 30 15 30 30 
Cigarettes 
per day 
8 10 10 2.5 3.5 1.5 20 13.5 
 
  49 
APPENDIX E 
Ferric Reducing Ability of Plasma assay instructions 
FERRIC REDUCING ABILITY OF PLASMA (FRAP) 
1. Collect and snap freeze plasma.  Store at -80 until analysis. 
Assay procedures:  Note: Remove and discard top layer of all solid chemicals before using 
1. Make up 300 mmol/L acetate buffer (adjust to pH 3.6)  
 a. weigh 3.1 grams sodium acetate trihydrate 
 b. add 16 ml acetic acid (1N) (Molarity = Normality/Valence) 
 c. bring to final volume of one liter with DI water 
2. Make up 10 mmol/L TPTZ (2,4,6 - tripyridyl-s-triazine) (store in refrigerator) (MW=312.3) in 40 mmol HCl (adjust to 
make 30 mL) 
a. make up 40 mmol/l HCl (Molarity = Normality/Valence) Examples: (330 uL HCl (12N) + 99.670 mL DDI water 
(in hood)  
b. weigh out 187.38 mg TPTZ 
 
c. add TPTZ to 60 mL  HCl, final concentration = 10 mmol and mix until dissolved. 
3. Make up 20 mmol/L iron trichloride hexhydrate (ITX) (MW=270.29) in DDI water (Make 100 mL) 
(0.54g ITX + 100 mL DI) 
4. Make up working FRAP solution (300 mL total volume) (Note: solution should be bright orange color, if color is dark 
purple or purple tinted, your iron hexhydrate was most likely pre-oxidized.) 
  
 a. measure out 250 ml acetate buffer 
 b. add 25 ml TPTZ solution 
 c. add 25 ml ITX solution 
This amount of solution is sufficient for 86 tests. 
7 STDs x 2 = 14 
1 BLK x 2 = 2 
35 samples x 2 = 70 
5. STD Curve.  Make up 100, 200, 400, 600, 800, and 1000 uM/L solutions of ascorbate/trolox in DI water. 
For ascorbate, measure 44 mg ascorbate + 250 mL DI to make 1000 uM ascorbate.  (Note: Consider using Trolox as 
STD).  you will have to calculate how to make the 1000uM trolox. 
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 1000uM Troloxate solution    DI 
1000 uM 5 mL     0 mL 
800 uM 4 mL     1 mL 
600 uM 3 mL     2 mL 
400 uM 2 mL     3 mL 
200 uM 1 mL     4 mL 
100 uM 0.5 mL     4.5 mL 
0 uM 0.0 mL     5.0 mL 
6. Warm FRAP solution to 37 deg C 
7. For BLK, samples, and ascorbate STDs, add 100 ul of DI, plasma sample, or STD, respectively to 3.0 mL FRAP reagent 
and vortex. 
8. Incubate tubes at 37 deg C for 4 min 
9. Measure absorbance (593 nm) immediately after 4 min. 
10. Report plasma reducing potential as ascorbate acid equivalents obtained from reference curve of ascorbate concentration 
(593nm).  ie... 1 umol ascorbate = one reducing equivalent. 
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APPENDIX F 
Oxygen Radical Absorbance Capacity assay instructions 
Standard Operating Procedure of Oxygen Radical Absorbance Capacity 
(ORACFL) 
 
                                                                                                                                                                                        Written by Xianli Wu, 
ACNC 
                          Last Modified: 
10/31/2005 
 
1. INSTRUMENTS AND SUPPLIES 
     1.1.       Necessary Instruments and Supplies: 
 Microplate Reader  with or without injectors and desktop PC with relevant software 
 Centrifuge and/or microcentrifuge 
 Water bath, 0-100 °C 
 Refrigerator, 4°C 
 Freezer, -20°C 
 Vortex apparatus  
 Pan balance 
 pH meter 
 Stir plate, magnetic 
 Analytical balance 
 Polypropylene or Polystyrene Assay Plate, 96 Well Clear Flat Bottom (Costar, Falcon 
etc.) 
 Pipettemen, 100-1000 µL, 50-200 µL, 10-100 µL (Eppendorf)  
 Pipette Tips, 20-200 µL, 101-1000 µL (Fisher) 
 Volumetric flasks, 1000, 100, 50, 25, 10, 2 mL 
 Graduated cylinders, 1000 mL, 250 mL and 100 mL. 
 Conical tubes 50 mL, 15 mL (Fisher) 
 Eppendorf tubes 1.8 mL 
 Sealing film (if plate does not include a cover) 
 Plastic transfer pipettes (Fisher) 
 
1.2. Optional Instruments and Supplies: 
 Automated Microplate Pipetting System with desktop PC and software 
 
  52 
 Repeating Multi-Channel Pipette, 20-200 µL with compatible tips and reagent 
reservoir 
 Timer 
 Orbital Shaker 
 
2. REAGENTS AND SOLVENTS 
 Trolox,  6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, Aldrich 
Chemicals, Item 238813- 5G, CAS# 53188-07-1, F.W. 250.29 
 Fluorescein disodium salt, Aldrich Chemicals, Item 166308-100G, CAS# 518-47-8, 
F.W. 376.28 
 AAPH, 2,2‟-Azobis(2-amidinopropane) dihydrochloride, Wako Chemicals, Item 992-
11062 RN# 2997-92-4. F. W. 271.193. 
 Potassium Phosphate Dibasic, Fisher Chemical, CAS# 7758-11-4, F.W. 174.18. 
 Potassium Phosphate Monobasic, J.T. Baker, item 4008-01, CAS# 7778-77-0, F.W. 
136.09 
 diH2O 
 
3. REAGENT PREPARATION  
       3.1. Phosphate Buffer 
 Buffer Stock Solution:   
        Solution A:  75 mMolar Monopotassium phosphate 
o Accurately weigh 10.21 grams of Monopotassium Phoshate into a weigh dish 
o Transfer the monopotassium phosphate into a 1000 mL volumetric flask 
o Add approximately 700 mL DI water and a magnetic stir bar.  Stir on a 
magnetic stirplate until the phosphate is dissolved 
o Remove the stir bar and make up to volume with DI water 
                  Solution B:  75 mMolar Dipotassium phosphate 
o Accurately weigh 13.06 grams of Dipotassium Phoshate into a weigh dish 
o Transfer the Dipotassium phosphate into a 1000 mL volumetric flask 
o Add approximately 700 mL DI water and a magnetic stir bar.  Stir on a 
magnetic stirplate until the phosphate is dissolved 
o Remove the stir bar and make up to volume with DI water 
 Buffer Working Solution: 
o Place a magnetic stir bar into a 1000 mL beaker. Pour 800 mLs of solution B 
into the 1000 mL beaker.  Insert the pH electrode and begin reading the pH 
of the solution. 
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o Transfer 200 mLs of solution A into a graduated cylinder. Transfer the A 
solution into the 1000 mL beaker containing B and monitor the change in pH.   
o Slowly add additional solution A as needed to reach a final solution pH of 
7.4 
o Store the 7.4 Buffer in a one liter amber glass bottle. 
         3.2. Trolox Standards                
 Trolox Stock Solution:  
Dissolve 25 mg (0.025 g) of Trolox in 100 mL phosphate buffer working solution to 
make 1 mM trolox, then dilute to 500 µM. Aliquot 1.5 mL in 1.8 mL Eppendorf 
tubes and store at –70°C until use. 
  Trolox Working Solution:   
 Thaw an aliquot of Trolox stock solution. Take 1 mL of 500 µM Trolox in a 15  mL 
tube; add 9 mL of working buffer and vortex to make 50 µM Trolox solution. 
Make serial dilutions of the 50 µM Trolox solution with working buffer 
solution to produce 25, 12.5, 6.25 µM Trolox standards.  Keep remaining 
Trolox solution at 4°C. 
   
        3.3. Fluorescein Solution   
 Fluorescein Stock solution:   
o Stock solution #1: dissolve 0.0225 g in 50 mL of working phosphate buffer 
and mix well. 
o Stock solution #2: dissolve 50 µL of stock solution #1 in 10 mL of working 
buffer and vortex. Aliquot stock solution #2 into 1.8 mL Eppendorf tubes 
and store at –20°C until use. 
 Fluorescein Working Solution:  
Pipette 800 µL of stock solution #2 into 50 mL phosphate buffer (for two runs) in a 50 mL 
conical tube. Before use, incubate in the water bath at 37°C until thoroughly heated. This 
solution can be kept in the water bath for many hours. 
 
        3.4. AAPH Solution   
The phosphate buffer is preincubated at 25 °C. Dissolve 0.108 g of AAPH into 5 mL of 
incubated phosphate buffer immediately before the start of the assay. This produces an 
AAPH solution containing  79.6 μmol/mL. A 20 μL aliquot provides 1.6 μmol AAPH 
per well.  It is important to keep the AAPH in the refrigerator at 4
o
C before adding the 
warm buffer. The AAPH reaction is temperature-dependent. This procedure was proven 
with the BMG plate reader to significantly reduce apparent temperature effects.   
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NOTE: If –20°C and –70°C storage facilities are not available, fresh reagent solutions 
have to be made freshly on a daily basis. 
 
 
4.  PREPARE AND LOAD 96-WELL MICROPLATE  
 
 Set up a paper layout to determine the order of your samples. In order to avoid 
possible positional errors, a “forward-then-reverse” order is recommended. It is 
highly recommended to leave the edge wells empty or blank (phosphate buffer 
working solution) to reduce the impact of “edge effect” on samples and standards 
particularly if your instrument exhibits some temperature effects on the outside wells. 
The following is an example of sample layout in a 96-well microplate:  
 
X B B B B B B B B B B B 
B T1 T2 T3 T4 B S1 S2 S3 S4 S5 B 
B S6 S7 S8 S9 S10 S11 S12 S13 S14 S15 B 
B B B B T1 T2 T3 T4 B B B B 
B S16 S17 S18 S19 S20 S20 S19 S18 S17 S16 B 
B S15 S14 S13 S12 S11 S10 S9 S8 S7 S6 B 
B S5 S4 S3 S2 S1 B T4 T3 T2 T1 B 
B B B B B B B B B B B B 
   X: 200 µL Fluorescein working solution for gain adjustment of plate reader. 
   B: Blank, phosphate buffer working solution. 
   S: Sample 
   T: Trolox standards, from T1 to T4, from 6.25 µM to 50 µM.       
 
 Pipette 20 µL of sample, blank and Trolox standard solutions into appropriate wells.  
Also pipette 200 µL of fluorescein working solution into the selected well for the gain 
adjustment. 
 
FOR PLATE READERS WITH 2 INJECTORS (eg. BMG Fluostar Galaxy/Optima plate 
reader): 
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 Place 25 mL Fluorescein working solution in the plate reader so that it corresponds to 
Pump #1. 
 
 Place the correct amount of AAPH solution in position so that it corresponds to Pump 
#2.   
 
5. SETTING THE PLATE READER 
5.1. BMG Fluostar galaxy/optima plate reader 
    Plate Reader Startup 
 From the Start Menu, select: Programs> BMG technologies> Fluostar 
galaxy/optima> Fluostar control. Click “incubator” icon and set the temperature at 37 
°C.  
 
  Click on the “open door” icon after the color of the “incubator” icon turns from 
red to green. Cover the plate with a lid or sealing film, insert the microplate, and click 
the “close door” icon.  Leave the plate in the chamber for ten minutes for pre-heating. 
 
  Click on the “Test Protocol” icon (The icon is located next to the setup icon on 
the Fluostar Optima brand instrument.  Use the “Test” icon for the Fluostar Galaxy 
brand instrument) to create or open an ORAC Fluostar Test Protocol.  Click on “new” 
or open an already existing test protocol.   
 
Layout 
Set up the layout exactly like the paper layout.  Trolox standards will be labeled as 
“sample.”  Fluorescein will be a “standard.”   
Basic Parameters  
            Positioning delay:  0.3s 
No. of kinetic windows: 1 
No. of cycles: 35 
Measurement Starting Time: 0.0 s 
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No. of flashes per cycle: 15 
Cycle time: Depending on the layout. 
Filters and integration: Fluorescence Intensity 
No. of multichromatics: 1 
Gain: will change depending on each Gain Adjustment 
Pause before cycle: 0 
Excitation filter: 485 nm 
Emission filter: 520 nm 
Calculation range: start from 1, stop at 35 
Click on “check timing” icon (lower left corner).  Note the cycle time.   
               Concentration/Volume/Shaking  
               Volume 1: 200 µL, Pump speed: 420 µL/s 
               Volume 2: 20 µL, Pump speed: 420 µL/s 
               Shaking mode: orbital 
               Shaking width: 4 mm 
               Additional Shaking: before each cycle 
               Shaking time: 8 s 
               Injection and timing for instruments with automatic pipettors as part of the 
plate reader: 
        Volume group 1 injection cycle: 2 
        Volume group 2 injection cycle: 4 
        Volume group 1 injection start time: 0.0 s 
        Volume group 2 injection start time: 0.0 s. 
 Place the injection needles and the tubes into their appropriate solution. The solution 
should pump back into its tube.   Pump 1 is for Fluorescein and pump 2 is for AAPH. 
Next, click on the „Prime‟ icon to prime the two pumps and remove any air bubbles.  
Prime each needle at least 3 times.  
 Open the microplate chamber and remove the lid or film.  Close the chamber again. 
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               Click the „measure‟ icon or select „measure‟ under the Measure menu. Select 
the correct test protocol.  Enter plate and sample identifications and check the gain 
adjustment for the fluorescein well.  The normal range of gain value is 35 ± 5 for 
Galaxy and 1700 ± 100 for Optima, at 90% required value.  
 Open the microplate chamber, cover the plate and leave it in the instrument for ten 
minutes.  Then, open the chamber once more, remove the cover, close the chamber, 
and start the test run. 
 
 NOTE  
 Make sure the incubator is on and the temperature is set to 37°C. 
 Make sure the cables are turned so as to read from the bottom of the plate. 
 Back flush old reagents from pumps after each run.  
 Two injection needles and measurement head need to be washed thoroughly at least every two 
days if the machine is fully used.  
 
Injection and timing for instruments without automatic pipettors as part of the plate reader: 
 
 Add 200 μL Fluoroscein working solution to each well using an 8 channel micropipettor. 
 Place cover on microplate and incubate plate and contents at 37 oC for at least 20 minutes. 
 Verify that plate reader is warmed up to 37 oC and ready to read samples. 
 Add 20 μL AAPH working solution using an 8 channel micropipettor. 
 
               NOTE: Timing of the addition of the AAPH is critical and the time to add all columns should be kept 
to a convenient minimum. An automated pipetting system was timed and it took about 8 
seconds per column for a total of 1 min 40 seconds to pipette the entire plate. This was 
sufficient time such that a difference in the initial reading was observed due to the reaction 
occurring in the 1
st
 column compared to the 12
th
 column. A sample layout of “forward then 
reverse” is critical in this case to account for timing differences. 
 
      
6. DATA ANALYSIS AND CALCULATIONS 
6. 1. Calculation of Area Under the Curve (AUC) 
          The relative area under curve (AUC) was calculated as 
AUC = (0.5 + f5 / f4 + f6 / f4 + f7 / f4 + … + fi / f4) × CT 
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Where fi = fluorescence reading at cycle i (i.e. f4 = initial fluorescence reading at 
cycle 4), and CT = cycle time in minutes.  
The net AUC was obtained by subtracting the AUC of the blank from that of a 
sample.  
NOTE: The AUC calculated in this SOP is a relative AUC, which means the initial point 
was treated as 1, so the other data points would range from 0 to 1.0. In terms of the 
calculation, the AUC was calculated as the sum of many small trapezoids. The 
formula is as follows:  
AUC = [(f1/f1 + f2/f1) × t]/2 +[(f2/f1 + f3/f1) × t]/2 + [(f3/f1 + f4/f1) × t]/2 +… + [(fi-1/f1 + 
fi/f1) × t]/2    =[0.5+ f2/f1+ f3/f1+… + fi-1/f1+( fi/f1)/2] × t 
 
6. 2. Calculation of ORACFL value       
The final ORACFL values were calculated by using a quadratic regression equation (y 
= a + bx + cx2) between Trolox concentration (μM) and the net area under the FL 
decay curve (net AUC). The quadratic regression was used in the range of 6.25-50 
μM Trolox. Data is expressed as micromoles of Trolox Equivalents (TE) per liter (for 
liquid sample) or per gram (for solid sample) of sample (μmol TE/L or μmol TE/g). 
 
               The data was analyzed by Microsoft Excel (Microsoft, Roselle, IL). 
 
 A quality control standard of gallic acid or uric acid can be included in each run. It is 
important to monitor the net area of the standards and the regression coefficients. 
 
USE THIS EQUATION TO SOLVE FOR FINAL CONCENTRATIONS: x = -b+ √b
2
-4ac+4cy 
  
7. Key References 
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APPENDIX G 
FRAP Data 
Subject Wpre Wpost45 Wpost245 Cpre Cpost45 Cpost245 
2 948.875 947.625 870.125 847.625 868.875 868.875 
3  1108.875 1070.125 1006.375 1027.625 1032.625 
6  1037 984.5 1083.875 1110.75 1107 
7 1220.75 1213.25 1189.5 1042 1003.875 1061.375 
11 1234.5 1268.875  1154.5 1220.125 1193.875 
12 1348.875 1507 1449.5 1368.875 1317 1344.5 
14 1367.625 1627.625 1497.625 1408.25 1457.625 1180.75 
15 944.5 1431.375 966.375 1172 1110.75 1087.625 
 
FRAP = Ferric Reducing Ability of Plasma, Wpre = wine pre consumption, Wpost45 = wine 
45 minutes post consumption, Wpost245 = wine 2 hours and 45 minutes post consumption, 
Cpre = control pre consumption, Cpost45 = control 45 minutes post consumption, Cpost245 
= control post 2 hours and 45 minutes. 
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APPENDIX H 
ORAC Data 
Subject  Wpre Wpost45 Wpost245 Cpre Cpost45 Cpost245 
2 39.85483 37.86606 40.00897 40.43463 37.38255 39.56575 
3 N/A 27.87225 34.43399 32.72482 45.71433 14.99088 
6 N/A 48.13496 49.41785 36.35119 47.24731 20.87101 
7 32.28554 41.87714 47.39213 26.54822 21.82394 52.85438 
11 34.43399 37.09556 N/A 20.87101 37.09556 32.28554 
12 31.17731 43.36692 28.77338 32.72482 44.40942 45.20204 
14 36.35119 41.8714 37.86606 46.1891 46.26145 51.63489 
15 48.26434 28.77338 46.06616 31.17731 28.31945 25.31793 
       
ORAC = Oxygen Radical Absorbance Capacity, Wpre = wine pre consumption, Wpost45 = 
wine 45 minutes post consumption, Wpost245 = wine 2 hours and 45 minutes post 
consumption, Cpre = control pre consumption, Cpost45 = control 45 minutes post 
consumption, Cpost245 = control post 2 hours and 45 minutes. 
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APPENDIX I 
Vascular Data 
 
See table on next page. 
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